[en] Inhibitors of COMT and MAO-B are well established in the pharmacotherapy of Parkinson's disease (PD). MAO-B inhibitors are used as monotherapy as well as in combination with levodopa, whereas COMT inhibitors exert their effects only in conjungtion with levodopa. Both classes of compounds prolong the response duration of levodopa and optimise its clinical benefit. As a result, the ON-times are prolonged significantly. In the past, MAO-B inhibitors were also adminstered for neuroprotection; however, despite convincing scientific reasoning in support of neuroprotective effects, these could not be substantiated in clinical studies performed so far.
Disciplines :
Neurologie
Auteur, co-auteur :
Woitalla, Dirk; Neurologische Klinik, Kathol. Kliniken der Ruhrhalbinsel.
KRÜGER, Rejko ; University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit
Lorenzl, Stefan; Paracelsus Medizinische Privatuniversität, Institut für Pflegewissenschaft und -praxis, Salzburg.
Müller, Thomas; lexianer St. Joseph Berlin-Weißensee GmbH, Berlin.
Oelwein, Guenther; Neurologische Praxis, Gera.
Storch, Alexander; Klinik und Poliklinik für Neurologie, Universität Rostock, und Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Rostock/Greifswald, Rostock.
Wolz, Martin; Klinik und Poliklinik für Neurologie, Elblandkliniken Meissen-Radebeul.
Wüllner, Ullrich; Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn & Deutsches Zentrum für neurodegenerative Erkrankungen (DZNE Bonn).
Co-auteurs externes :
yes
Langue du document :
Allemand
Titre :
Grundlagen und Stellenwert der COMT- und MAO-B-Inhibitoren in der Therapie des idiopathischen Parkinson-Syndroms.
Titre traduit :
[en] The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease
